A Phase I clinical trial with a dual ICOS/CD28 antagonist engineered for use in autoimmune and inflammatory diseases.
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2017
At a glance
- Drugs ALPN 101 (Primary)
- Indications Autoimmune disorders; Inflammation
- Focus Adverse reactions
- 24 Apr 2017 New trial record
- 18 Apr 2017 Accoording to a Nivalis Therapeutics media release, company plans to initiate this trial in the second half of 2018.